This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
BP Q4 underlying recoverable cost profit +65% YoY to $3.4bn, beating $2.9bn consensus, underlying op. cash flow +14.5% also beat. Upstream profit +74.8%, downstream +47.1%, Rosneft +34.2%. Upstream production +1.8%. Dividend +2.5%. Expects FY’19 underlying production higher, but Q1 expected flat as North Sea/Alaska divestments offset by BHP asset acquisitions.
Ocado FY18 Retail revs +12%, Solutions +15.8%, Costs +19.1%, Retail EBITDA +4.2%, Group EBITDA -20%; Net loss quadruples; Partner Fees +37%, Cash +174% (now net cash); FY19 retail revs seen +10-15% further Retail EBITDA growth, CAPEX £350m (+66% vs +33% in 2018). No CFCs opening in 2019, Solutions revs growth to be ahead of Retail, but decline in EBITDA due to £15-20m extra op costs.
Indivior denied rehearing by US Court of Appeals after CAFC vacated preliminary injunction against Dr Reddy’s. Indivior intends to file emergency motion, assuming Dr Reddy’s and Alvogen will resume launches of generic sublingual film in US once CAFC issues mandates on 11 Feb and 31 Jan, respectively. Indivior branded version could lose 80% of market.
(Sources: Company newswires, Bloomberg, CNBC, FT, Reuters, Wall Street Journal)
For more information on any of these individual news items, call into the trading floor
| Stock | Code | Close | High | Low |
| RYANAIR | RYA | 1.4% | 1.6% | -1.8% |
| FERREXPO | FXPO | -6.6% | 0.0% | -11.8% |
| SERCO | SRP | 2.4% | 3.3% | -0.6% |
| INDIVIOR | INDV | -0.3% | 6.2% | -1.5% |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.
Prepared by Michael van Dulken, Head of Research